Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAT-3247 phase 2a trial in ambulatory boys with Duchenne muscular dystrophy
ACTRN12625001370493Phase 2Not yet recruiting
- Sponsor
- Satellos Bioscience Inc.
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of forazapadin in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by Satellos Bioscience Inc. Primary endpoints: Safety of SAT-3247, Tolerability of SAT-3247 and 1 more. Planned start May 2026; status: not yet recruiting.
02
Drugs
forazapadin
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on ACTRN12625001370493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001370493.